Table 4.
|
|
rPBP3
c
|
Bla
d
|
Proportions (%) of isolates and patients |
|||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Groups of isolates
b
|
n
|
n
|
% |
n
|
% |
Anatomical sites |
Age groups |
Hospitalized
e
|
|||
Eye | Ear | Respiratory | 0-3 | ≥50 | |||||||
Resistant group |
177 |
116 |
66 |
16 |
9 |
28 |
10 |
58 |
44 |
24 |
33 |
Susceptible group |
19 |
0 |
0 |
0 |
0 |
21 |
32 |
42 |
68 |
5 |
11 |
Remaining isolates |
599 |
0f |
0f |
60g |
10g |
19 |
15 |
63 |
41 |
22 |
23 |
Original population | 795h | 116 | 15 | 76 | 10 | 21 | 14 | 62 | 43 | 22 | 25 |
aNORM 2007 surveillance population [33], consisting of consecutive routine isolates from patients with eye, ear and respiratory tract infections.
bSee text and Figure 1 for definition of the study groups (Resistant group and Susceptible group).
cPBP3-mediated resistance (see Table 1).
dBeta-lactamase positive.
eProportions of patients hospitalized at the time of sampling.
fAssuming that all rPBP3 isolates were selected for the Resistant group.
gAs reported by the primary laboratories.
hThirteen isolates were selected for the Resistant group but excluded for various reasons (see Figure 1).